Gyre Therapeutics (GYRE) Free Cash Flow (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Free Cash Flow of $3.0 million for Q1 2026, up 1303.98% year-over-year from $215244.6 in Q1 2025, and up 152.7% quarter-over-quarter from -$5.7 million in Q4 2025.
Gyre Therapeutics (GYRE) Free Cash Flow (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Free Cash Flow for 17 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 1303.98% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.1 million (up 134.91% YoY), while the FY2025 annual figure was -$180000.0, up 96.98% from the prior year.
- Free Cash Flow improved to $3.0 million in Q1 2026 per GYRE's latest filing, from -$5.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $42.3 million in Q4 2022 and bottomed at -$12.3 million in Q2 2022.
- Historically, Free Cash Flow has averaged $1.5 million across 5 years, with a median of $1.0 million in 2023.
- Annual changes were most pronounced in 2024 — Free Cash Flow plunged 437.99% — and 2026, when it jumped 1303.98%.
- Gyre Therapeutics' Free Cash Flow stood at $42.3 million in 2022, then plunged by 97.55% to $1.0 million in 2023, then sank by 359.94% to -$2.7 million in 2024, then plunged by 112.92% to -$5.7 million in 2025, then surged by 152.7% to $3.0 million in 2026.
- Business Quant data shows GYRE's Free Cash Flow at $3.0 million in Q1 2026, -$5.7 million in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -17.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.01 Mn |
| Jun 30, 2026 | -17.01 Mn |
| Mar 31, 2026 | 3.02 Mn |
| Mar 31, 2026 | 3.02 Mn |
| Dec 31, 2025 | -5.73 Mn |
| Dec 31, 2025 | -5.73 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | -251,000.00 |
| Mar 31, 2025 | -251,000.00 |
| Dec 31, 2024 | -2.69 Mn |
| Dec 31, 2024 | -2.69 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | -6.95 Mn |
| Jun 30, 2024 | -6.95 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Mar 31, 2024 | 2.65 Mn |